Includes meal plans, supplements, and guidance
Liraglutide has been shown to produce an average weight loss of around 8-10% of body weight
Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide
Tirzepatide is also FDA-approved under the brand name Zepbound for chronic weight management in eligible adults, along with reduced-calorie eating and increased physical activity
For many people, this difference alone tips the decision toward tirzepatide
Our exclusive Beauty IV Therapy, also known as GlowRadiance, is a revolutionary treatment designed to rejuvenate and revitalize from within